For decades, the KRAS gene was written off as a lost cause. Its surface, smooth and featureless, offered no obvious place for a drug to grab hold. Pancreatic cancer, driven by KRAS mutations in more than 90% of cases, remained one of the fastest killers in oncology. That calculus has now shifted.
Daraxonrasib, an experimental oral drug from Revolution Medicines, works through an indirect but powerful mechanism. It grabs a helper molecule called cyclophilin A. Together, they form a complex that clamps onto active KRAS and shuts down its growth signal. The approach targets multiple RAS mutations at once, making it harder for the cancer to develop resistance. That breadth matters in a disease where tumors are genetically messy.
The Phase 3 trial enrolled 500 patients with metastatic pancreatic cancer who had already received prior treatment. These are patients with few options left. Standard chemotherapy gave them a median survival of 6.7 months. Daraxonrasib pushed that to 13.2 months. That is a 60% reduction in the risk of death. Nearly double the survival time. For a cancer where treatment advances have been incremental at best, these numbers land with force.
Side effects are real but manageable. Most patients developed a skin rash. Others dealt with mouth sores, diarrhea, and nausea. Still, patients on the drug were less likely to stop treatment than those on chemotherapy. They also reported a better quality of life. That last point matters more than it might seem. In advanced cancer, the goal is not just more time. It is more time that feels worth living.
The results were published in the New England Journal of Medicine. Experts quoted in the report describe daraxonrasib as potentially the most significant advance in pancreatic cancer treatment in a generation. That is not a phrase researchers toss around lightly. Pancreatic cancer has defeated drug after drug. The five-year survival rate for metastatic disease remains in the single digits. Anything that moves the needle is rare. Something that doubles survival is unprecedented.
The drug still awaits regulatory approval. That process is not guaranteed. The Food and Drug Administration will weigh the trial data, the side effect profile, and the durability of the response. But the evidence from this Phase 3 trial is strong. A 60% reduction in the risk of death in a heavily pretreated population is hard to dismiss.
If approved, daraxonrasib would change the treatment landscape for pancreatic cancer. It would also validate a new approach to targeting KRAS. For years, researchers tried and failed to bind the protein directly. The cyclophilin A workaround opens a path not just for pancreatic cancer but potentially for other KRAS-driven tumors. Lung cancer, colorectal cancer, and some forms of ovarian cancer also carry KRAS mutations. The same mechanism could apply.
That is still speculative. For now, the focus is on pancreatic cancer. The trial results offer a glimmer of hope for a patient population that has had very little. The drug is not a cure. It does not eliminate the disease. But it buys time. And in this field, time is the scarce resource.
